An Open Label Multicentric Phase II Study of Panitumumab (Vectibix) in Cutaneous Squamous Cell Carcinoma (SCC).

Next Previous
Trial Profile

An Open Label Multicentric Phase II Study of Panitumumab (Vectibix) in Cutaneous Squamous Cell Carcinoma (SCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms PASCE

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Mar 2017 Status changed from recruiting to completed.
    • 27 Aug 2010 Actual initiation date (Aug 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top